JP4504559B2 - 新リポポリアミン、その調製および適用 - Google Patents

新リポポリアミン、その調製および適用 Download PDF

Info

Publication number
JP4504559B2
JP4504559B2 JP2000509683A JP2000509683A JP4504559B2 JP 4504559 B2 JP4504559 B2 JP 4504559B2 JP 2000509683 A JP2000509683 A JP 2000509683A JP 2000509683 A JP2000509683 A JP 2000509683A JP 4504559 B2 JP4504559 B2 JP 4504559B2
Authority
JP
Japan
Prior art keywords
compound
salt
case
octadecyl
hexadecenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000509683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515060A5 (https=
JP2001515060A (ja
Inventor
ローラント クレーゼル，
ステファン ケーニッヒ，
Original Assignee
ビオンテックス ラボラトリーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19834683A external-priority patent/DE19834683A1/de
Application filed by ビオンテックス ラボラトリーズ ゲーエムベーハー filed Critical ビオンテックス ラボラトリーズ ゲーエムベーハー
Publication of JP2001515060A publication Critical patent/JP2001515060A/ja
Publication of JP2001515060A5 publication Critical patent/JP2001515060A5/ja
Application granted granted Critical
Publication of JP4504559B2 publication Critical patent/JP4504559B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/42—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having etherified hydroxy groups and at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000509683A 1997-08-13 1998-08-13 新リポポリアミン、その調製および適用 Expired - Fee Related JP4504559B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19735125 1997-08-13
DE19834683A DE19834683A1 (de) 1997-08-13 1998-07-31 Neue Lipopolyamine, deren Darstellung und Anwendung
DE19834683.2 1998-07-31
DE19735125.5 1998-07-31
PCT/EP1998/005156 WO1999008997A1 (de) 1997-08-13 1998-08-13 Neue lipopolyamine, deren darstellung und anwendung

Publications (3)

Publication Number Publication Date
JP2001515060A JP2001515060A (ja) 2001-09-18
JP2001515060A5 JP2001515060A5 (https=) 2010-05-06
JP4504559B2 true JP4504559B2 (ja) 2010-07-14

Family

ID=26039111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000509683A Expired - Fee Related JP4504559B2 (ja) 1997-08-13 1998-08-13 新リポポリアミン、その調製および適用

Country Status (8)

Country Link
US (1) US6281371B1 (https=)
EP (1) EP1003711B1 (https=)
JP (1) JP4504559B2 (https=)
AT (1) ATE208369T1 (https=)
AU (1) AU745958B2 (https=)
CA (1) CA2299429C (https=)
ES (1) ES2167939T3 (https=)
WO (1) WO1999008997A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052858A2 (en) * 1998-04-08 1999-10-21 Celltech Therapeutics Limited Lipids
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
WO2000064858A1 (en) * 1999-04-26 2000-11-02 Celltech R&D Limited Bipolar lipids and their use for the delivery of bioactive substances
WO2001043778A1 (en) * 1999-12-17 2001-06-21 Gene Therapy Systems, Inc. Use of cationic lipids for intracellular protein delivery
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US7001925B1 (en) 2002-09-27 2006-02-21 University Of Central Florida Research Foundation, Inc. Compounds and method for enhancing the efficacy of anti-cancer drugs
US7906122B2 (en) * 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
EP1638919B1 (en) * 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
US20110045001A1 (en) * 2008-03-28 2011-02-24 Biontex Laboratories Gmbh Transfection results of non-viral gene delivery systems by influencing of the innate immune system
WO2013016058A1 (en) * 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
WO2016075154A1 (en) 2014-11-10 2016-05-19 Ethris Gmbh Induction of osteogenesis by delivering bmp encoding rna
HUE065017T2 (hu) 2019-02-14 2024-04-28 Ethris Gmbh Poliribonukleotid ciliogenezisre gyakorolt hatásának elemzése
WO2022096582A1 (en) 2020-11-04 2022-05-12 Ethris Gmbh Use of ifn-lambda mrna for treating viral infections
WO2024121160A1 (en) 2022-12-05 2024-06-13 Ethris Gmbh Regulator(s) of energy homeostasis-encoding rna molecule(s) with increased translation efficiency

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963189A1 (de) 1969-12-17 1971-06-24 Bayer Ag Verfahren zur Herstellung von flammfesten,Urethangruppen aufweisenden Schaumstoffen
US4339767A (en) 1980-05-05 1982-07-13 International Business Machines Corporation High performance PNP and NPN transistor structure
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5538722A (en) 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
DE4139001A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen
US5972600A (en) 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
GB9218762D0 (en) 1992-09-04 1992-10-21 Exxon Chemical Patents Inc Esters
HUT73383A (en) 1993-03-19 1996-07-29 Boehringer Sohn Ingelheim Process for preparing cancer vaccines
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
WO1996040726A1 (en) 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
AU707734B2 (en) 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
EP0840744A4 (en) 1995-06-07 1999-03-10 Genta Inc CATIONIC LIPIDS BASED ON PHOSPHONIC ACID
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US6020526A (en) * 1995-07-21 2000-02-01 Genta, Incorporated Amide-based cationic lipids
DE19607686A1 (de) 1996-02-29 1997-09-04 Chemicon Lab Gmbh Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung
US5747509A (en) 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)

Also Published As

Publication number Publication date
AU9342198A (en) 1999-03-08
CA2299429A1 (en) 1999-02-25
CA2299429C (en) 2010-04-20
WO1999008997A1 (de) 1999-02-25
AU745958B2 (en) 2002-04-11
US6281371B1 (en) 2001-08-28
JP2001515060A (ja) 2001-09-18
EP1003711A1 (de) 2000-05-31
EP1003711B1 (de) 2001-11-07
ATE208369T1 (de) 2001-11-15
ES2167939T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
US11446394B2 (en) Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
JP4504559B2 (ja) 新リポポリアミン、その調製および適用
Zhang et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery
KR100807060B1 (ko) 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는전달체
JP2007521247A (ja) 生体適合性−遺伝子送達剤としての新規カチオン性リポポリマー
US20100004315A1 (en) Biodegradable Cross-Linked Branched Poly(Alkylene Imines)
AU3366901A (en) Novel colloid synthetic vectors for gene therapy
CA2217550A1 (en) Cationic lipids for gene therapy
CN108136050A (zh) 转染络合物和其使用方法
WO2023232148A1 (zh) 一种含有不饱和键的氨基酸阳离子脂质
US20220323594A1 (en) Lipidated cationic peptide-peg compositions for nucleic acid delivery
US20130079383A1 (en) Lipid Compounds Targeting VLA-4
JP2001515060A5 (https=)
KR100909786B1 (ko) 올리고 펩티드를 수식한 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는 전달체
US11098006B2 (en) Lipids and complexes for the delivery of biologically-active material to cells
DE19834683A1 (de) Neue Lipopolyamine, deren Darstellung und Anwendung
EP4480943A1 (en) New class of lipids for delivering active ingredients into cells
Patel Development of Amino Acid-Modified Drug Delivery Systems for RNA Delivery in Cancer Therapeutics
Zhao et al. Cationic liposomes in different structural levels for gene delivery
CN121241051A (zh) 一种含氮杂环和甘氨酸的阳离子脂质
CN118598764A (zh) 可电离脂质化合物、组合物及应用
Wang Phytanyl substituted asymmetric gemini surfactant-based transfection vectors for gene therapy
MXPA00005481A (en) Transfection particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090728

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090828

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100308

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100406

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100423

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130430

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees